Mingche Biotech Secures Tens of Millions in Series A Funding to Advance Full-Chain Minimally Invasive Ophthalmic Devices
MINGCHE
Ophthalmic Medical Device Researcher
【Viewpoint · Ophthalmology Industry Navigation】
Major Events Monthly Report | Editor's Recommended Article
Winning Atlas· Centralized Procurement Scaling Up | Ophthalmic Optometry Column
Recently, MINGCHEMINGCHE Biotechnology (Suzhou) Co., Ltd. (referred to as: "MINGCHE Technology")CompletedTens of Millions of Yuan in Series A Financing, byNanjing Innovation Investment Group、Yuanhe HoldingsAndCHUANGU CAPITALJoint Investment. The funds from this round will be mainly used to advanceMinimally Invasive Glaucoma Drainage TubeNMPA and CE Registration of MIGS, AcceleratedHydrogel Drainage Device and Implantable IOP SensorThe research and development iteration; at the same time, the company will also promotePosterior Chamber Phakic ICL LensThe construction of pilot plant and clinical transformation.
MINGCHE, founded in 2021, has established a system around "minimally invasive ophthalmic diagnosis and treatment."A Complete Product System Covering the Anterior and Posterior Segments of the EyeThe company's current pipeline already covers multiple tracks, such as minimally invasive glaucoma drainage, retinal aspiration micro-needles for the fundus, posterior chamber ICL lenses, and vascular interventional micro-nano robots, laying the foundation for establishing an integrated platform for diagnosis, treatment, and long-term monitoring in the future.
The core team of the company is composed of senior industry experts.Founder Dr. Dongni RenShe has deep expertise in high-end implantable medical devices and 3D printing, accumulating extensive experience in R&D and industrialization. During her business expansion, she systematically analyzed the trends and market landscape of minimally invasive glaucoma treatment, ultimately focusing on the MIGS field—a domain with both technological barriers and clinical demand—for entrepreneurship. She is committed to promoting domestic innovation in ophthalmic minimally invasive surgical devices in China.
In terms of regulatory and clinical progress, MINGCHEMINGCHE's Minimally Invasive Glaucoma Drainage Tube Enters NMPA's Special Review Process for Class III Innovative Medical Devices, Launching the Green Channel; The self-developed fundus irrigation and aspiration needle has been approved for the Class II medical device registration certificate; posterior chamber ICLCrystal SystemThe system has completed the material and process finalization and entered the system verification phase; the micro-nano interventional robot platform has also completed multiple rounds of large animal experiments and achieved phased results.
In addition, MINGCHEMINGCHEInAdvance the Systematic Solution of "Drainage + Monitoring", integrating aqueous humor drainage, intraocular pressure monitoring, and chronic disease management into a single technical framework, providing a new technological pathway for the long-term management of glaucoma and the accumulation of real-world data.
Overall, this round of financing will help MINGCHE.Further Improve the Overall Layout of Minimally Invasive Ophthalmology, from key product registration, material system verification to global standard application, forming an upward channel from surgical innovation to platform expansion. MINGCHE will also continue to advance the landing of its product lines in the directions of refractive surgery, minimally invasive glaucoma treatment, and long-term monitoring, while gradually expanding into overseas markets.
# Drainage - Monitoring - Refraction - Intervention Full-chain Layout
MINGCHE's current product portfolio has covered multiple key treatment scenarios in both anterior and posterior segments of the eye, includingThe Minimally Invasive Glaucoma Surgery (MIGS) series is currently the most advanced core pipeline.。
Independently developed by the companyGELA® Glaucoma Drainage TubeIt has entered the NMPA's special review process for Class III innovative medical devices and is conducting registration evaluation work in accordance with the requirements of the innovation channel.
The product's efficacy and safety have been validated through systematic clinical trials.The surgical approach is becoming more minimally invasive., aiming to supplement new technical options between traditional glaucoma surgery and existing MIGS solutions.
(a)-(c) Micrographs of the front segment, transition segment, and tail end of the drainage stent; Micro-drainage stent patency test: (d) Slowly push the syringe, liquid overflows at the stent outlet; (e), (f) Slowly push the syringe, bubbles emerge from the stent in pure water.
Centered on the MIGS track, the company has simultaneously laid out its strategy.Hydrogel Drainage Device and Implantable IOP Sensor：
The mechanical and anti-scarring properties of hydrogel materials have been iteratively optimized, enhancing implant safety while significantly improving cost structure.
The implantable intraocular pressure sensor serves as a crucial component of the "drainage + monitoring" integrated solution, aiming to enable continuous postoperative intraocular pressure data collection, thereby providing a foundation for the long-term management of glaucoma and real-world research.
In the aspect of minimally invasive instruments for the posterior segment of the eye:
MINGCHE's independently developedMINGCHE's Eye Bottom Injection and Aspiration Needle has obtained the Class II Medical Device Registration Certificate., which can be used in surgical scenarios such as subretinal injection and aspiration, combining minimally invasive operation, needle stability, and retinal protection. It belongs to one of the medical device categories currently accelerating localization in China.
In the field of refraction：
MINGCHE TechnologyThe posterior chamber type with crystal refractive lens (ICL) and its supporting system have completed the finalization of materials and processes., and entered the systematic validation phase. This crystal utilizes a new type of composite biomaterial, focusing on enhancing anti-protein adhesion, mechanical flexibility, and optical transparency to meet the requirements for long-term implantation.
Frontier Exploration：
Company LayoutAlthough vascular interventional micro-nano robots are still in the early stages of global research and development, but has completed multiple rounds of large-scale animal experiments to explore the feasibility of minimally invasive interventions in ophthalmology and broader organ systems. Although this direction is still in its early stages, it represents a potential route for MINGCHE's exploration of a cross-organ minimally invasive platform.
Overall, the common direction of this product line is: throughMaterial Systems, Micro Devices, and Sensing MonitoringThe establishment of a full-link minimally invasive platform from surgical treatment to long-term management.
# From "Product-Oriented" Company to "Platform-Oriented" Ecosystem
After entering a new R&D cycle, MINGCHE's planning direction has gradually shifted from "single product advancement" to "Minimally Invasive + Intelligent + Platform-Based"The construction of the system. Focusing on diseases with high incidence and significant long-term management needs such as glaucoma, refractive errors, and posterior segment conditions, the company is accelerating the development of a product portfolio that covers diagnosis, treatment, and monitoring."
In the aspect of minimally invasive treatmentMINGCHE will continue to advance the process optimization and registration pace of the MIGS series, while simultaneously conducting parallel development around key elements such as implantable sensors and hydrogel materials, with the aim of integrating surgical outcomes, postoperative complication control, and long-term data collection into the same technical pathway in the future.
Refractive FieldThe ICL lens is also advancing in synchronization through pilot testing and clinical transformation, and in the future, it may form a product structure with iterative synergy among clinical consumables, implantable devices, and related systems.
At the same time, MINGCHE is trying toFurther Extension of Multiple Platform CapabilitiesFor example, based on the foundation of miniaturized instruments, flexible materials, and precision drive technology, the company is validating the feasibility of using micro-nano robots for interventions in more complex organs (such as nerves and cardiovascular systems). This area is still in the early stages of research and development, but the direction itself holds potential for interdisciplinary integration and larger-scale application scenarios.
In the industrialization path, MINGCHE's goal is not limited to the commercialization of a single product, but rather through the combination of various types of devices,Building a Continuously Scalable "Ophthalmic Minimally Invasive Technology Platform"。
MINGCHE plans to deepen cooperation with key ophthalmic centers in China, promoting product validation through clinical research, medical-engineering collaboration projects, and the accumulation of real-world data. Meanwhile, as some devices enter the registration or clinical stage, the company is also preparing to simultaneously expand into overseas markets and participate in discussions and formulation of certain international standards, laying the groundwork for the globalization of multiple product pipelines.
Overall, MINGCHE's medium- and long-term direction isFocusing on minimally invasive diagnosis and treatment, promoting the systematic combination of devices, materials, and sensing technologies in ophthalmic scenarios., gradually forming a leap from individual products to platform capabilities. For the ophthalmic device industry, which is still in rapid change, these platform enterprises that combine material innovation, minimally invasive techniques, and long-term monitoring capabilities may become important nodes in the future industrial chain.
# A New Phase of China-Made Substitution
From minimally invasive glaucoma drainage devices, refractive lenses to micro-nano robots, MINGCHE is striving to build a technological chain in ophthalmic instruments that covers diagnosis, treatment, and long-term management. As key products enter the registration, verification, or pilot testing phase, the company's R&D pace is transitioning from early exploration to systematic advancement.
The competition in the ophthalmology sector is shifting from breakthroughs in single devices to a contest of systematic capabilities — includingMaterial innovation, minimally invasive procedure iteration, intelligent monitoring, and cross-scenario interventional technologyMINGCHE's product structure and platform-based strategy may offer more possibilities in this round of the industry cycle. As funding is replenished and clinical collaborations continue to expand, the progress of its multiple pipelines will become one of the key windows for observing advancements in minimally invasive ophthalmic technology in China.
GOC2025
Ophthalmology Solutions Case
Ophthalmic Instruments Industry Research
Statement
Copyright Statement:The original article "Eye Future" is copyrighted by Beijing Siyu Bot Technology Co., Ltd. Without authorization, it cannot be reproduced, excerpted, or mirrored on other websites, WeChat Official Accounts, or commercial platforms. For reprinting, please contact the backend to obtain authorization. This platform reserves the right to pursue legal responsibilities for unauthorized full-text reproduction, rewriting, or paraphrasing.
